Toronto, Ontario - Theralase Technologies Inc. (“Theralase” or the “Company”) ($TLT:CA) ($TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has submitted an Investigational Testing Authorization (“ITA”) for its anti-cancer technology to Health Canada for approval.
The ITA details information about the proprietary Theralase TLC-3200 Oncology Laser System, which Theralase plans to use to activate the Company’s lead Photo Dynamic Compound (“PDC”), TLD-1433, to destroy Non-Muscle Invasive Bladder Cancer (“NMIBC”).
Pending approval of the following applications, Theralase plans to commence enrolling patients inflicted with NMIBC into a Phase Ib clinical study at Princess Margaret Cancer Center, University Health Network (“UHN”) to prove the primary objective of safety and tolerability, with an exploratory objective of efficacy:
- Health Canada Clinical Trial Application (“CTA”) (Complete);
- Health Canada ITA (Complete);
- UHN Research Ethics Board (“REB”).
Roger Dumoulin-White, President and CEO, Theralase stated, “The submission of an ITA to Health Canada for NMIBC is yet another advancement for the Company in its quest to prove the safety, tolerability and efficacy of its anti-cancer technology in the destruction of NMIBC. Pending approval of the CTA, ITA and REB, UHN will commence enrolling and treating patients inflicted with this deadly disease.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) ($TLT:CA) ($TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Director of Investor Relations
1.866.THE.LASE (843-5273) ext. 222
416.699.LASE (5273) ext. 222
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer